https://www.sciencedirect.com/science/article/pii/S2468294222000910?via%3Dihub
Teaching an old dog new tricks: The case of Fenbendazole
https://pubmed.ncbi.nlm.nih.gov/42203321/
Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort
https://www.mdpi.com/1422-0067/23/8/4315
Message from Sonny:
Double Repositioning: Veterinary Antiparasitic to Human Anticancer
https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1795402/full
Management of advanced HR-positive breast cancer using metabolically supported chemotherapy and repurposed drugs: a case report
https://link.springer.com/article/10.1186/s13058-022-01591-3
Mebendazole prevents distant organ metastases in part by decreasing ITGβ4 expression and cancer stemness
https://www.mdpi.com/1422-0067/23/1/519
Flubendazole Plays an Important Anti-Tumor Role in Different Types of Cancers
Repurposed, off-label drugs as new and effective cancer treatments: Top 25
https://pubmed.ncbi.nlm.nih.gov/36854536/
Redox-mediated Anticancer Activity of Anti-parasitic Drug Fenbendazole in Triple-negative Breast Cancer Cells
https://www.mdpi.com/1420-3049/26/17/5118
Anticancer Effect of Benzimidazole Derivatives, Especially Mebendazole, on Triple-Negative Breast Cancer (TNBC) and Radiotherapy-Resistant TNBC In Vivo and In Vitro
https://pubmed.ncbi.nlm.nih.gov/38131223/
A novel treatment to enhance survival for end-stage triple-negative breast cancer using repurposed veterinary anthelmintics combined with gut‑supporting/immune enhancing molecules
https://link.springer.com/article/10.1007/s11060-024-04654-x
Repurposing mebendazole against triple‑negative breast cancer CNS metastasis
https://www.mdpi.com/2072-6694/15/4/1330
Mebendazole Treatment Disrupts the Transcriptional Activity of Hypoxia-Inducible Factors 1 and 2 in Breast Cancer Cells
https://www.researchsquare.com/article/rs-3915392/v1
Repurposing mebendazole against triple-negative breast cancer leptomeningeal disease
Conclusion
In summary, MBZ was a safe and effective oral agent in an aggressive animal model of TNBC LMD. MBZ may function by selectively targeting migrating tumor cells. These findings align with previous efforts involving MBZ and CNS pathology and further support the drug’s potential utility as an alternative therapy for TNBC LMD.
https://link.springer.com/article/10.1186/s13058-022-01591-3
Mebendazole prevents distant organ metastases in part by decreasing ITGβ4 expression and cancer stemness
https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1596694/full
Fenbendazole induces pyroptosis in breast cancer cells through HK2/caspase-3/GSDME signaling pathway
https://www.mdpi.com/1648-9144/58/9/1239
Antidiabetics, Anthelmintics, Statins, and Beta-Blockers as Co-Adjuvant Drugs in Cancer Therapy
https://www.mdpi.com/2072-6694/14/19/4601
Repurposing of Benzimidazole Anthelmintic Drugs as Cancer Therapeutics
https://www.sciencedirect.com/science/article/pii/S2211383522003999
Benzimidazole and its derivatives as cancer therapeutics: The potential role from traditional to precision medicine
https://pubmed.ncbi.nlm.nih.gov/30196056/
Mebendazole Potentiates Radiation Therapy in Triple-Negative Breast Cancer
https://www.canceractive.com/article/an-offlabel%20drugs%20protocol%20for%20cancer
Building an off-label drugs protocol for cancer?
https://pubmed.ncbi.nlm.nih.gov/39355784/
Anticancer role of flubendazole: Effects and molecular mechanisms (Review)
Flubendazole, an anthelmintic agent with a well-established safety profile, has emerged as a promising anticancer drug, demonstrating efficacy against a spectrum of cancer types over the past decade.
https://pubmed.ncbi.nlm.nih.gov/40605964/
Fenbendazole Case Reports: 3 Stage IV Cancers in Remission (2025 Case Series)
This article is for research and informational purposes only. It does not constitute medical advice and is not a substitute for professional oncology consultation. Always discuss any investigational protocol with your physician. This article was retracted. However, it’s still worth a read. --Retraction Statement: Paper by William Makis, Ilyes Baghli, and Pierrick Martinez entitled “Fenbendazole as an Anticancer Agent? A Case Series of Self-Administration in Three Patients” [Case Rep Oncol. 2025;18:856-863; https://doi.org/10.1159/000546362]
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0345701
Repurposing mebendazole to reprogram oncogenic and tumor-suppressor networks: Multi-cancer insights from ENOX2, MMP2, RASSF1A, WFDC10A and METTL7A
https://www.mdpi.com/1420-3049/31/12/2070
PEG-b-PCL Micelles as Nanocarriers for Poorly Soluble Benzimidazoles: A Comparative Study of Albendazole and Fenbendazole
https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.670804/full
Repositioning of Antiparasitic Drugs for Tumor Treatment
This is an excellent list. Thanks so much!